Adaptive Biotechnologies ADPT Other Commercial Liabilities
Other Commercial Liabilities at other companies
Other financials
Where this comes from
Reported directly by Adaptive Biotechnologies in its filing.
Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.
The official record: Adaptive Biotechnologies’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adaptive Biotechnologies's other commercial liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adaptive Biotechnologies's other commercial liabilities?
- Adaptive Biotechnologies (ADPT) reported other commercial liabilities of $7.47M in Q1 2026.
- How has Adaptive Biotechnologies's other commercial liabilities changed year-over-year?
- Adaptive Biotechnologies's other commercial liabilities decreased by 3.8% year-over-year, from $7.76M to $7.47M.
- What is the long-term trend for Adaptive Biotechnologies's other commercial liabilities?
- Over 5 years (2020 to 2025), Adaptive Biotechnologies's other commercial liabilities has grown at a -10.2% compound annual growth rate (CAGR), from $13.16M to $7.7M.